THC Global Group Ltd reached numerous milestones in the June quarter, providing its first Australian patient with Canndeo branded medicinal cannabis medicines produced from a Southport Facility. The roll-out of the full collection of Canndeo medicines is ongoing throughout this quarter and will see the introduction of eight new medicine formulations for Australian patients. THC is preparing for its earliest export of Canndeo branded medicines to Europe and Canada, with supply expected to commence in quarter three for Canada and quarter four for Europe. Furthermore, THC Global has plans for New Zeland exports, Hydroponics equipment advancement, and the Company’s newly acquired clinic network, Tetra Health.
– Medical Marijuana Program Connection, 08/03/2020 5:30:02 AM